{"title":"CCR5拮抗剂:对抗艾滋病毒的新工具","authors":"Boris Jülg, Frank-Detlef Goebel","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Chemokine receptors are essential for cell entry by HIV. The two chemokine receptors most relevant to this process are CC chemokine receptor 5 (CCR5) and CXC chemokine receptor 4 (CXCR4) since a delayed onset of disease can be achieved by inhibition of either receptor. Therefore, chemokine receptor antagonists, in particular inhibitors of CCR5, represent a promising new class of anti-HIV agents. In this review, we summarise current drug candidates, give an insight into how they interact with CCR5, and discuss requirements and restrictions for these compounds.</p>","PeriodicalId":81665,"journal":{"name":"Journal of HIV therapy","volume":"10 4","pages":"68-71"},"PeriodicalIF":0.0000,"publicationDate":"2005-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"CCR5 antagonists: a new tool in fighting HIV.\",\"authors\":\"Boris Jülg, Frank-Detlef Goebel\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Chemokine receptors are essential for cell entry by HIV. The two chemokine receptors most relevant to this process are CC chemokine receptor 5 (CCR5) and CXC chemokine receptor 4 (CXCR4) since a delayed onset of disease can be achieved by inhibition of either receptor. Therefore, chemokine receptor antagonists, in particular inhibitors of CCR5, represent a promising new class of anti-HIV agents. In this review, we summarise current drug candidates, give an insight into how they interact with CCR5, and discuss requirements and restrictions for these compounds.</p>\",\"PeriodicalId\":81665,\"journal\":{\"name\":\"Journal of HIV therapy\",\"volume\":\"10 4\",\"pages\":\"68-71\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2005-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of HIV therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of HIV therapy","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Chemokine receptors are essential for cell entry by HIV. The two chemokine receptors most relevant to this process are CC chemokine receptor 5 (CCR5) and CXC chemokine receptor 4 (CXCR4) since a delayed onset of disease can be achieved by inhibition of either receptor. Therefore, chemokine receptor antagonists, in particular inhibitors of CCR5, represent a promising new class of anti-HIV agents. In this review, we summarise current drug candidates, give an insight into how they interact with CCR5, and discuss requirements and restrictions for these compounds.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
